In the last ten years, the mechanical circulatory support (MCS) has become a valuable therapeutic option in patients with end-stage congestive heart failure. Several generations of devices have been developed, but they are mainly designed for adult population. The only available device developed particularly to infants and small children is Berlin Heart pulsatile system. Its superiority in long-term MCS compared to extracorporeal membrane oxygenation (ECMO) has been established [1], demonstrating at the same time many disadvantages, such as neurological complications, cases of pump thrombosis, necessity of readmissions and important limitations of quality of life. At present, the intracorporeal continuous-flow left ventricular assist device (CF-LVAD) provides excellent patient mobility and low complication rates in the adult population. In the adult population, continuous-flow devices completely dominate over pulsatile ones, representing more than 90 % (12,030 of 13,286 primary implants for left heart support) of the durable VADs implanted between 2006 and 2014 [1]. This phenomenon is driven primarily by improved profile of complications and durability of continuous-flow VADs compared with pulsatile ones. With ongoing device miniaturization, enthusiasm has been growing among pediatricians in terms of the use of continuous-flow VADs in children. According to the first PediMACS report, approximately one-half (54 %; 109 of 200) of the long-term devices registered are continuous-flow ones [2]. With the results recorded to date, the use of continuous-flow devices in the pediatric population is rapidly increasing. Continuous-flow VADs compose 62 % (179 of 291) of